Clinical trials: Acute Myeloid Leukemia (AML) With
Leukemia
Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia
RATIONALE: Giving chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00274846
- Testing
- aldesleukin, therapeutic allogeneic lymphocytes, cyclophosphamide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia, Myeloid, Acute
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
The goal of this clinical trial is to learn if participants treated with the experimental drug cusatuzumab added to venetoclax and azacitidine works to treat acute myeloid leukemia (AML) compared to venetoclax and azacitidine.
- Trial name
- NCT06384261
- Testing
- Cusatuzumab, Venetoclax, Azacitidine
- Where
- 38 sites in United States, Canada and 3 more
- Volunteers
- 140 people
- Sponsor
- OncoVerity, Inc.
Leukemia
Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R
RATIONALE: Giving chemotherapy before an autologous stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
- Trial name
- NCT00534469
- Testing
- aldesleukin, filgrastim, busulfan
- Volunteers
- 60 people
- Sponsor
- City of Hope Medical Center
AML
HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML
Acute myeloid leukemia (AML) is the most common leukemia in China, with a high incidence in elderly patients (≥60 years), who comprise over half of all cases (median age ~68 years).
- Trial name
- NCT06744556
- Testing
- daunorubicin, Venetoclax, cytarabine
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Leukemia
Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002805
- Testing
- filgrastim, cladribine, cytarabine
- Where
- 38 sites in United States, Australia and 1 more
- Volunteers
- 115 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS)
Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome
The CL1-64315-001 study is a phase I, international, multicentre, open-label, non-randomised, non-comparative study. This study is designed in two parts: one part for dose escalation, one part for dose expansion.
- Trial name
- NCT02979366
- Testing
- S64315 once a week, S64315 twice a week
- Where
- 9 sites in United States, Australia and 2 more
- Volunteers
- 38 people
- Sponsor
- Institut de Recherches Internationales Servier
Acute Myelogenous Leukemia, Acute Myeloid Leukemia
A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II)
Clolar (clofarabine injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior…
- Trial name
- NCT00373529
- Testing
- clofarabine
- Where
- 20 sites in United States
- Volunteers
- 116 people
- Sponsor
- Genzyme, a Sanofi Company
CD33 Positive Acute Myelogenous Leukemia
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
An expanded access/compassionate use protocol that allows access to Mylotarg for relapsed/refractory AML CD33 positive patients in the USA. Contact: B1761026@iconplc.com
- Trial name
- AML (NCT02312037)
- Testing
- Antibody Drug Conjugate Chemotherapeutic
- Where
- 142 sites in United States
- Sponsor
- Pfizer
Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
This phase I/II trial studies the side effects and best dose of ONC201 and to see how well it works in treating patients with acute leukemia or high-risk myelodysplastic syndrome that has returned after a period of improvement…
- Conditions
- Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT02392572
- Testing
- Akt/ERK Inhibitor ONC201, Venetoclax
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, in Relapsed or Refractory, Acute Myeloid Leukemia, Elderly, Unfit
Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy
This phase II trial studies how well tislelizumab combined with DNA hypomethylation agent +/- CAG regimen (cytarabine, idarubicin / Aclarithromycin, rhG-CSF/ PEG-rhG-CSF) work in treating patients with high-risk acute myeloid…
- Conditions
- Acute Myeloid Leukemia, in Relapsed or Refractory, Acute Myeloid Leukemia, Elderly, Unfit, Acute Myeloid Leukemia With Positive Minimal Residual Disease
- Trial name
- NCT04541277
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Chinese PLA General Hospital
Acute Bilineal Leukemia, Acute Biphenotypic Leukemia
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
This will be a phase II, open-label, non-randomized study with a safety lead-in phase. There are 3 Arms in this study each with 2 parts. If you are eligible, you will be assigned to an Arm and a part when you join the study.
- Conditions
- Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
- Trial name
- NCT02397720
- Testing
- Azacitidine, Ipilimumab, Venetoclax
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- M.D. Anderson Cancer Center
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Acute Myeloid Leukemia (AML)
Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
This is a 4-stage, non-randomized, open-label, dose escalation and expansion, multicenter study. A cycle of therapy is 21 days. Stage 1 was a dose-escalation stage.
- Trial name
- NCT02113982
- Testing
- Tagraxofusp
- Where
- 9 sites in United States
- Volunteers
- 138 people
- Sponsor
- Stemline Therapeutics, Inc.
Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic diseases.
- Conditions
- Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm
- Trial name
- NCT06013423
- Testing
- Biospecimen Collection, Bone Marrow Aspirate, Cyclophosphamide
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Fred Hutchinson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
RATIONALE: A personalized Internet-based program may help improve fatigue, depression, and quality of life in long-term survivors of stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00799461
- Testing
- internet-based intervention, questionnaire administration, psychosocial assessment and care
- Where
- United States
- Volunteers
- 1,337 people
- Sponsor
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Acute Myeloid Leukemia
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
The researchers are doing this study to find out whether a 3-drug combination of ivosidenib, azacitidine, and venetoclax followed by maintenance therapy with ivosidenib alone is an effective treatment approach for people with…
- Trial name
- NCT07392242
- Testing
- Ivosidenib, Azacitidine, Venetoclax
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
This phase II trial tests how well ruxolitinib with tacrolimus and methotrexate work to prevent the development of graft versus host disease in pediatric and young adult patients undergoing allogeneic hematopoietic cell…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT06128070
- Testing
- Biospecimen Collection, Chest Computed Tomography, Echocardiography
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- City of Hope Medical Center
AML
LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)
The purpose of this study is to evaluate the effectiveness of post-induction lenalidomide in patients with de novo AML with deletion 5q cytogenetic abnormality (del (5q)) or monosomy 5 (-5), who obtained complete remission after…
- Trial name
- NCT01198054
- Testing
- Lenalidomide
- Where
- 12 sites in Spain
- Volunteers
- 4 people
- Sponsor
- PETHEMA Foundation
aGVHD, Acute Myelogenous Leukemia
Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
The purpose of this study is to see if see if adding the specific combination of donors can result in acceptable levels of survival without evidence of disease.
- Conditions
- aGVHD, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT06904482
- Testing
- Haplo-Identical / Cord Blood Transplant
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Case Comprehensive Cancer Center
Leukemia, Myelodysplastic Syndromes
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy…
- Trial name
- NCT00027924
- Testing
- busulfan, cyclosporine, fludarabine phosphate
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a)
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia
This phase I trial studies the side effects of donor stem cell transplant in treating patients with high risk acute myeloid leukemia.
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2)
- Trial name
- NCT01801046
- Testing
- mitoxantrone hydrochloride, cytarabine, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Southern California
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.